miv-cel's BLA in stiff person syndrome tests whether a single-arm CAR-T dataset can clear FDA's bar and unlock a rare-disease franchise

Bull

FDA grants approval based on the KYSA-8 dataset, crediting the statistically significant T25FW improvement (median 46%, p=0.0003), the clean safety profile with no high-grade CRS or ICANS, and the 100% immunotherapy-free rate as sufficient evidence given the unmet need in this ultra-rare disease. Approval under RMAT designation with priority review would establish miv-cel as the first disease-modifying therapy in SPS, create a defensible rare-disease franchise, and provide a commercial and regulatory blueprint for expansion into gMG and other autoimmune indications.

Bear

FDA determines that a single-arm trial of 26 patients without a randomized control arm is insufficient to establish efficacy, particularly given the subjective and variable natural history of SPS, and issues a Complete Response Letter requesting a controlled study. The most likely failure modes are FDA concern about endpoint interpretability in the absence of a placebo arm, questions about the durability of T25FW improvement beyond 16 weeks as a surrogate for meaningful functional benefit, or manufacturing or CMC deficiencies identified during rolling review that delay or derail the submission.